

Readable Form, submitted in accordance with 37 CFR 1.821, including 1.821(c) and 1.821(e) are identical. No new matter has been added by these amendments.

RECEIVED


APR 27 2000

TECH CENTER 1600 2000

Favorable consideration of this application is respectfully requested.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6938


Myra H. McCormack, Ph.D.
Attorney for Applicants
Reg. No. 36,602

Date: April 18, 2000